Structure-guided design of anti-cancer ribonucleotide reductase inhibitors
Ribonucleotide reductase (RR) catalyses the rate-limiting step of dNTP synthesis, establishing it as an important cancer target. While RR is traditionally inhibited by nucleoside-based antimetabolites, we recently discovered a naphthyl salicyl acyl hydrazone-based inhibitor (NSAH) that binds reversi...
Main Authors: | Tessianna A. Misko, Yi-Ting Liu, Michael E. Harris, Nancy L. Oleinick, John Pink, Hsueh-Yun Lee, Chris G. Dealwis |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-01-01
|
Series: | Journal of Enzyme Inhibition and Medicinal Chemistry |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/14756366.2018.1545226 |
Similar Items
-
Advances of Ribonucleotide Reductase Inhibitors on Cancer
by: WANG An'ge, et al.
Published: (2019-08-01) -
Herpes simplex ribonucleotide reductase
by: Ingemarson, Rolf
Published: (1989) -
Design and synthesis of potential ribonucleotide reductase enzyme (RNR) inhibitors as antileukemic and/or antiviral 2′-deoxymethylene nucleosides
by: Khairia M. Youssef, et al.
Published: (2015-12-01) -
Ribonucleotide reductase inhibitors: a new look at an old target for radiosensitization
by: Tobias eChapman, et al.
Published: (2012-01-01) -
Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors
by: Kentaro Minami, et al.
Published: (2015-03-01)